SlideShare a Scribd company logo
1 of 4
Download to read offline
KARYOTYPING
Foreword
The obstetric care of a pregnancy, as it is practiced today, includes invasive procedures
for the definitive prenatal diagnosis of fetal disorders correlations dependant on the
results of the chromosomal analysis made upon fetal cells. Sex chromosome trisomies
(SCT), an extra X chromosome in females
(triple X, XXX), males with an extra X
chromosome (Klinefelter syndrome, XXY)
or an extra Y chromosome (XYY) occur
because of errors during meiosis and are
relatively frequent in humans. Their
identification has never been the goal of
prenatal diagnosis (PD) but they almost
escape detection. Testing for serious
genetic abnormalities is more likely to
uncover these trisomies. The indications
to perform prenatal cytogenetic diagnosis
for numerical chromosomal abnormalities
include: abnormal results of prenatal double or triple test, advanced maternal age, fetal
abnormality detected through ultrasound examination, and positive family history for
chromosomal anomalies. Only such an intervention will permit answers to the dilemma
of whether to terminate the pregnancy or to carry it to term.
Dr. Prakash Trivedi
MD [O&G], IVF specialist, Mumbai
Introduction
At conception 23 chromosomes are passed
from each parent to the embryo. The correct
number
of
chromosomes
that
the
cells/embryos should have is 46. However,
there is a statistical chance that one
chromosome will be missing or that one extra
chromosome is present. When this happens it
is termed fetal aneuploidy. Depending on the
chromosomal
abnormality
fetal
loss,
developmental and speech delays, growth
delays, and sexual characteristics may fail to
develop. Down syndrome is an example
where an extra copy of chromosome 21 is
present.
Background
Trisomy 21 (Down syndrome) is associated with mental retardation, malformation of the
heart, gastrointestinal tract, eyes and ears. The overall risk of having an affected fetus is
one in 1,000 live births. Down syndrome is caused by an extra 21st chromosome and is
characterized by mental retardation and specific physical characteristics. It has long
1
been accepted that women who are 35 years or
older at the time of delivery should be offered
prenatal diagnosis with amniocentesis or
chorionic villus sampling.
Although the risk for trisomy 21 increases with
maternal age, an estimated 75% of affected
fetuses are born to mothers younger than 35
years. Because of this risk, it is important to
provide pregnant women who are younger than
35 years with noninvasive screening for this
trisomy.

Trisomy 18 (Edwards’ syndrome) occurs
in one in every 6,000 births and is
associated with low birth weight, mental
retardation and cranial, cardiac and
renal malformations. Trisomy 18 is also
caused by extra genetic material (an
extra 18th chromosome). Children with
trisomy 18 have severe mental
retardation and life-threatening birth
defects. Most infants affected with this
trisomy die within the first year of life. All
three analytes (AFP, hCG, and UE3)
help test for Down syndrome and
trisomy 18.
Approach
1. As a routine between 15-22 week of pregnancy;
2. If the the screening test reveals abnormal analyte levels, then an ultrasound is
usually recommended because it can sometimes identify the reason for an abnormal
result such as a misdated pregnancy, twins or a birth defect.
3. Amniocentesis will also be offered to test more accurately for spina bifida, Down
syndrome and trisomy 18;
4. If a birth defect is detected, several options may be available including increased
surveillance of the pregnancy, arrangements for special care needed at delivery, or
discontinuation of the pregnancy.
Result interpretation
However, it has to be borne in mind
that a normal triple maternal
screening test does not mean a baby
has no neural tube defect, Down
syndrome or trisomy 18. This is
because the maternal serum triple
2
screen does not detect every case of Down syndrome, trisomy 18 or spina bifida. We
estimate that it detects 85% of neural tube defects, 80% of pregnancies with Down
syndrome, and 80% of pregnancies with trisomy 18.
Summary

Summary
Findings from one study has categorically revealed that STDMS [second trimester
double marker] is optimal for the detection of fetal DS [Down’s syndrome] in pregnant
women aged under 35. For individual women, if economic condition permits, [second
trimester triple marker] STTMS is the best choice, while for women aged above 35,
STTMS is the best choice in this regard. Noninvasive alternatives to the triple test have
been identified, but these have not been adopted despite 13 years of development. It is
likely, therefore, that the triple test (or variants thereof) will continue to be used in
routine antenatal care for the foreseeable future.
Reference:

3
1. Am J Med Genet A. 2013 Nov;161A(11):2873-9, Counseling parents before prenatal
diagnosis: do we need to say more about the sex chromosome aneuploidies?
Lalatta F, Tint GS.
2.

4

More Related Content

What's hot

Down syndrome
Down syndromeDown syndrome
Down syndromeYaduNand1
 
Translucência nucal
Translucência nucalTranslucência nucal
Translucência nucalgisa_legal
 
From down syndrome screening to nipt
From down syndrome screening to niptFrom down syndrome screening to nipt
From down syndrome screening to niptPathKind Labs
 
Van Wyke-Grumbach syndrome and pituitary hyperplasia in a six-year-old girl
Van Wyke-Grumbach syndrome and pituitary hyperplasia in a six-year-old girlVan Wyke-Grumbach syndrome and pituitary hyperplasia in a six-year-old girl
Van Wyke-Grumbach syndrome and pituitary hyperplasia in a six-year-old girlApollo Hospitals
 
Process Of Genetic Screening
Process Of Genetic ScreeningProcess Of Genetic Screening
Process Of Genetic ScreeningFarsana Ashiq
 
Gene screen technology
Gene screen technologyGene screen technology
Gene screen technologyMiriya Johnson
 
prenatal diagnosis
prenatal diagnosis prenatal diagnosis
prenatal diagnosis ployswift
 
Fetal therapy - unborn patient (2019)
Fetal therapy - unborn patient (2019)Fetal therapy - unborn patient (2019)
Fetal therapy - unborn patient (2019)Dolly Bashani
 
Prenatal diagnosis and fetal therapy
Prenatal diagnosis and fetal therapyPrenatal diagnosis and fetal therapy
Prenatal diagnosis and fetal therapyMohit Satodia
 
Down’s syndrome/ NIPT or NIFTY is the bes/t sharda jain/Amniocentesis
Down’s syndrome/ NIPT or NIFTYis the bes/t sharda jain/AmniocentesisDown’s syndrome/ NIPT or NIFTYis the bes/t sharda jain/Amniocentesis
Down’s syndrome/ NIPT or NIFTY is the bes/t sharda jain/AmniocentesisLifecare Centre
 
Birth defects and prenatal diagnosis
Birth defects and prenatal diagnosisBirth defects and prenatal diagnosis
Birth defects and prenatal diagnosisMarami Mustapa
 
Klinefelter syndrome
Klinefelter syndromeKlinefelter syndrome
Klinefelter syndromePeter Egorov
 

What's hot (20)

Genetic testing
Genetic testingGenetic testing
Genetic testing
 
Triple maternal screen
Triple maternal screenTriple maternal screen
Triple maternal screen
 
Cnmnpcpsp
CnmnpcpspCnmnpcpsp
Cnmnpcpsp
 
Maternal screening in Pregnancy (Double & quadruple marker)
Maternal screening in Pregnancy (Double & quadruple marker)Maternal screening in Pregnancy (Double & quadruple marker)
Maternal screening in Pregnancy (Double & quadruple marker)
 
Down syndrome
Down syndromeDown syndrome
Down syndrome
 
Translucência nucal
Translucência nucalTranslucência nucal
Translucência nucal
 
Iufd
IufdIufd
Iufd
 
Prenatal diagnosis
Prenatal diagnosis Prenatal diagnosis
Prenatal diagnosis
 
From down syndrome screening to nipt
From down syndrome screening to niptFrom down syndrome screening to nipt
From down syndrome screening to nipt
 
Van Wyke-Grumbach syndrome and pituitary hyperplasia in a six-year-old girl
Van Wyke-Grumbach syndrome and pituitary hyperplasia in a six-year-old girlVan Wyke-Grumbach syndrome and pituitary hyperplasia in a six-year-old girl
Van Wyke-Grumbach syndrome and pituitary hyperplasia in a six-year-old girl
 
Process Of Genetic Screening
Process Of Genetic ScreeningProcess Of Genetic Screening
Process Of Genetic Screening
 
Gene screen technology
Gene screen technologyGene screen technology
Gene screen technology
 
prenatal diagnosis
prenatal diagnosis prenatal diagnosis
prenatal diagnosis
 
Fetal therapy - unborn patient (2019)
Fetal therapy - unborn patient (2019)Fetal therapy - unborn patient (2019)
Fetal therapy - unborn patient (2019)
 
Rpl.nka
Rpl.nkaRpl.nka
Rpl.nka
 
Prenatal diagnosis and fetal therapy
Prenatal diagnosis and fetal therapyPrenatal diagnosis and fetal therapy
Prenatal diagnosis and fetal therapy
 
Down’s syndrome/ NIPT or NIFTY is the bes/t sharda jain/Amniocentesis
Down’s syndrome/ NIPT or NIFTYis the bes/t sharda jain/AmniocentesisDown’s syndrome/ NIPT or NIFTYis the bes/t sharda jain/Amniocentesis
Down’s syndrome/ NIPT or NIFTY is the bes/t sharda jain/Amniocentesis
 
Birth defects and prenatal diagnosis
Birth defects and prenatal diagnosisBirth defects and prenatal diagnosis
Birth defects and prenatal diagnosis
 
Rpl
RplRpl
Rpl
 
Klinefelter syndrome
Klinefelter syndromeKlinefelter syndrome
Klinefelter syndrome
 

Similar to Karyotyping

trisomy 18 and trisomy 13.pptx
trisomy 18 and  trisomy 13.pptxtrisomy 18 and  trisomy 13.pptx
trisomy 18 and trisomy 13.pptxBeBee13
 
Prenatal Assessment Risks Paper
Prenatal Assessment Risks PaperPrenatal Assessment Risks Paper
Prenatal Assessment Risks PaperRobin Morales
 
Sridhar prenatal diagnosis
Sridhar prenatal diagnosisSridhar prenatal diagnosis
Sridhar prenatal diagnosisSridhar Mulaka
 
PRENATAL TESTING AND DIAGNOSIS.pdf
PRENATAL TESTING AND DIAGNOSIS.pdfPRENATAL TESTING AND DIAGNOSIS.pdf
PRENATAL TESTING AND DIAGNOSIS.pdfOM VERMA
 
PRENATAL TESTING AND DIAGNOSIS.pdf
PRENATAL TESTING AND DIAGNOSIS.pdfPRENATAL TESTING AND DIAGNOSIS.pdf
PRENATAL TESTING AND DIAGNOSIS.pdfOM VERMA
 
Facts About Down Syndrome
Facts About Down SyndromeFacts About Down Syndrome
Facts About Down SyndromeDr Ann Tan
 
Research Paper On Patau Syndrome
Research Paper On Patau SyndromeResearch Paper On Patau Syndrome
Research Paper On Patau SyndromeSusan Migliaccio
 
Chronic Leukemia Investigation
Chronic Leukemia InvestigationChronic Leukemia Investigation
Chronic Leukemia InvestigationElizabeth Brooks
 
Understanding Down Syndrome
Understanding Down SyndromeUnderstanding Down Syndrome
Understanding Down SyndromeMarilyn Marie
 
Genetic sonogram and soft tissue markers
Genetic sonogram and soft tissue markersGenetic sonogram and soft tissue markers
Genetic sonogram and soft tissue markersMohit Satodia
 

Similar to Karyotyping (20)

trisomy 18 and trisomy 13.pptx
trisomy 18 and  trisomy 13.pptxtrisomy 18 and  trisomy 13.pptx
trisomy 18 and trisomy 13.pptx
 
Prenatal Assessment Risks Paper
Prenatal Assessment Risks PaperPrenatal Assessment Risks Paper
Prenatal Assessment Risks Paper
 
Sridhar prenatal diagnosis
Sridhar prenatal diagnosisSridhar prenatal diagnosis
Sridhar prenatal diagnosis
 
PRENATAL TESTING AND DIAGNOSIS.pdf
PRENATAL TESTING AND DIAGNOSIS.pdfPRENATAL TESTING AND DIAGNOSIS.pdf
PRENATAL TESTING AND DIAGNOSIS.pdf
 
PRENATAL TESTING AND DIAGNOSIS.pdf
PRENATAL TESTING AND DIAGNOSIS.pdfPRENATAL TESTING AND DIAGNOSIS.pdf
PRENATAL TESTING AND DIAGNOSIS.pdf
 
Facts About Down Syndrome
Facts About Down SyndromeFacts About Down Syndrome
Facts About Down Syndrome
 
prenatal diagnosis.ppt..pptx
prenatal diagnosis.ppt..pptxprenatal diagnosis.ppt..pptx
prenatal diagnosis.ppt..pptx
 
Down syndrome
Down syndromeDown syndrome
Down syndrome
 
Tay-Sachs Disorder
Tay-Sachs DisorderTay-Sachs Disorder
Tay-Sachs Disorder
 
Genetics
GeneticsGenetics
Genetics
 
Feta anomalies
Feta anomaliesFeta anomalies
Feta anomalies
 
Turner's Syndrome
Turner's SyndromeTurner's Syndrome
Turner's Syndrome
 
Research Paper On Patau Syndrome
Research Paper On Patau SyndromeResearch Paper On Patau Syndrome
Research Paper On Patau Syndrome
 
Chronic Leukemia Investigation
Chronic Leukemia InvestigationChronic Leukemia Investigation
Chronic Leukemia Investigation
 
Fetal Medicine
Fetal MedicineFetal Medicine
Fetal Medicine
 
Understanding Down Syndrome
Understanding Down SyndromeUnderstanding Down Syndrome
Understanding Down Syndrome
 
5. Genetics.pptx
5. Genetics.pptx5. Genetics.pptx
5. Genetics.pptx
 
Genetic sonogram and soft tissue markers
Genetic sonogram and soft tissue markersGenetic sonogram and soft tissue markers
Genetic sonogram and soft tissue markers
 
IUFD.pptx
IUFD.pptxIUFD.pptx
IUFD.pptx
 
Down Syndrome Essay
Down Syndrome EssayDown Syndrome Essay
Down Syndrome Essay
 

More from BALASUBRAMANIAM IYER (20)

Project Status Report PowerPoint Template.pptx
Project Status Report PowerPoint Template.pptxProject Status Report PowerPoint Template.pptx
Project Status Report PowerPoint Template.pptx
 
dyslipidemia6.ppt
dyslipidemia6.pptdyslipidemia6.ppt
dyslipidemia6.ppt
 
Cancer and immunology
Cancer and immunologyCancer and immunology
Cancer and immunology
 
Stem cells in cardiac care
Stem cells in cardiac careStem cells in cardiac care
Stem cells in cardiac care
 
Telmisartan combination uses
Telmisartan combination usesTelmisartan combination uses
Telmisartan combination uses
 
Infiximab
InfiximabInfiximab
Infiximab
 
Temisartan + chlorthalidone
Temisartan + chlorthalidoneTemisartan + chlorthalidone
Temisartan + chlorthalidone
 
Rrt
RrtRrt
Rrt
 
1
11
1
 
News2
News2News2
News2
 
Cilnidipine
CilnidipineCilnidipine
Cilnidipine
 
NGAL - Acute kidney injury biomarker
NGAL - Acute kidney injury biomarkerNGAL - Acute kidney injury biomarker
NGAL - Acute kidney injury biomarker
 
Are all arbs the same?
Are all arbs the same?Are all arbs the same?
Are all arbs the same?
 
Amh test
Amh testAmh test
Amh test
 
Ca
CaCa
Ca
 
Amh
AmhAmh
Amh
 
Torch
TorchTorch
Torch
 
Risk stratification in post cardiac event cases
Risk stratification in post cardiac event casesRisk stratification in post cardiac event cases
Risk stratification in post cardiac event cases
 
Presentation on heart valve devices
Presentation on heart valve devicesPresentation on heart valve devices
Presentation on heart valve devices
 
Anti platelet therapy
Anti platelet therapyAnti platelet therapy
Anti platelet therapy
 

Recently uploaded

Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...Ganesan Yogananthem
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
World-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxWorld-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxsumanchaulagain3
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxkitati1
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 

Recently uploaded (20)

Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
World-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxWorld-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptx
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptx
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 

Karyotyping

  • 1. KARYOTYPING Foreword The obstetric care of a pregnancy, as it is practiced today, includes invasive procedures for the definitive prenatal diagnosis of fetal disorders correlations dependant on the results of the chromosomal analysis made upon fetal cells. Sex chromosome trisomies (SCT), an extra X chromosome in females (triple X, XXX), males with an extra X chromosome (Klinefelter syndrome, XXY) or an extra Y chromosome (XYY) occur because of errors during meiosis and are relatively frequent in humans. Their identification has never been the goal of prenatal diagnosis (PD) but they almost escape detection. Testing for serious genetic abnormalities is more likely to uncover these trisomies. The indications to perform prenatal cytogenetic diagnosis for numerical chromosomal abnormalities include: abnormal results of prenatal double or triple test, advanced maternal age, fetal abnormality detected through ultrasound examination, and positive family history for chromosomal anomalies. Only such an intervention will permit answers to the dilemma of whether to terminate the pregnancy or to carry it to term. Dr. Prakash Trivedi MD [O&G], IVF specialist, Mumbai Introduction At conception 23 chromosomes are passed from each parent to the embryo. The correct number of chromosomes that the cells/embryos should have is 46. However, there is a statistical chance that one chromosome will be missing or that one extra chromosome is present. When this happens it is termed fetal aneuploidy. Depending on the chromosomal abnormality fetal loss, developmental and speech delays, growth delays, and sexual characteristics may fail to develop. Down syndrome is an example where an extra copy of chromosome 21 is present. Background Trisomy 21 (Down syndrome) is associated with mental retardation, malformation of the heart, gastrointestinal tract, eyes and ears. The overall risk of having an affected fetus is one in 1,000 live births. Down syndrome is caused by an extra 21st chromosome and is characterized by mental retardation and specific physical characteristics. It has long 1
  • 2. been accepted that women who are 35 years or older at the time of delivery should be offered prenatal diagnosis with amniocentesis or chorionic villus sampling. Although the risk for trisomy 21 increases with maternal age, an estimated 75% of affected fetuses are born to mothers younger than 35 years. Because of this risk, it is important to provide pregnant women who are younger than 35 years with noninvasive screening for this trisomy. Trisomy 18 (Edwards’ syndrome) occurs in one in every 6,000 births and is associated with low birth weight, mental retardation and cranial, cardiac and renal malformations. Trisomy 18 is also caused by extra genetic material (an extra 18th chromosome). Children with trisomy 18 have severe mental retardation and life-threatening birth defects. Most infants affected with this trisomy die within the first year of life. All three analytes (AFP, hCG, and UE3) help test for Down syndrome and trisomy 18. Approach 1. As a routine between 15-22 week of pregnancy; 2. If the the screening test reveals abnormal analyte levels, then an ultrasound is usually recommended because it can sometimes identify the reason for an abnormal result such as a misdated pregnancy, twins or a birth defect. 3. Amniocentesis will also be offered to test more accurately for spina bifida, Down syndrome and trisomy 18; 4. If a birth defect is detected, several options may be available including increased surveillance of the pregnancy, arrangements for special care needed at delivery, or discontinuation of the pregnancy. Result interpretation However, it has to be borne in mind that a normal triple maternal screening test does not mean a baby has no neural tube defect, Down syndrome or trisomy 18. This is because the maternal serum triple 2
  • 3. screen does not detect every case of Down syndrome, trisomy 18 or spina bifida. We estimate that it detects 85% of neural tube defects, 80% of pregnancies with Down syndrome, and 80% of pregnancies with trisomy 18. Summary Summary Findings from one study has categorically revealed that STDMS [second trimester double marker] is optimal for the detection of fetal DS [Down’s syndrome] in pregnant women aged under 35. For individual women, if economic condition permits, [second trimester triple marker] STTMS is the best choice, while for women aged above 35, STTMS is the best choice in this regard. Noninvasive alternatives to the triple test have been identified, but these have not been adopted despite 13 years of development. It is likely, therefore, that the triple test (or variants thereof) will continue to be used in routine antenatal care for the foreseeable future. Reference: 3
  • 4. 1. Am J Med Genet A. 2013 Nov;161A(11):2873-9, Counseling parents before prenatal diagnosis: do we need to say more about the sex chromosome aneuploidies? Lalatta F, Tint GS. 2. 4